ABBOTT LABORATORIES Other Comprehensive Income (Loss), Net of Tax
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Net of Tax of -$2.21 billion for the 3-month period ending 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2015-11-05
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for the quarter ending 2015-09-30 was -$2.21B.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for the quarter ending 2015-06-30 was $603.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for the quarter ending 2015-03-31 was -$681.00M, a 973.08% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for the quarter ending 2014-12-31 was -$2.08B, a 291.52% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for fiscal 2014 was -$3.04B, a 631.64% decline from fiscal 2013.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for fiscal 2013 was $572.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for fiscal 2012 was -$997.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), net of tax for fiscal 2011 was -$917.00M.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 6 month as first filed | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 9 month as first filed | Other Comprehensive Income (Loss), Net of Tax 12 month | Other Comprehensive Income (Loss), Net of Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | -$2.21B 10-Q · filed 2015-11-05 | -$1.60B derived: sum of 2 quarters · filed 2015-11-05 | -$2.29B 10-Q · filed 2015-11-05 | -$4.36B derived: sum of 4 quarters · filed 2015-11-05 | ||||
| 2015-06-30 | $603.00M 10-Q · filed 2015-08-04 | -$78.00M 10-Q · filed 2015-08-04 | -$2.16B derived: sum of 3 quarters · filed 2015-08-04 | -$3.18B derived: sum of 4 quarters · filed 2015-11-05 | ||||
| 2015-03-31 | -$681.00M 10-Q · filed 2015-05-06 | -$2.76B derived: sum of 2 quarters · filed 2015-05-06 | -$3.78B derived: sum of 3 quarters · filed 2015-11-05 | -$3.80B derived: sum of 4 quarters · filed 2015-11-05 | ||||
| 2014-12-31 | -$2.08B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$3.10B derived: sum of 2 quarters · filed 2015-11-05 | -$3.12B derived: sum of 3 quarters · filed 2015-11-05 | -$3.04B 10-K · filed 2015-02-27 | ||||
| 2014-09-30 | -$1.02B 10-Q · filed 2015-11-05 | -$1.04B derived: sum of 2 quarters · filed 2015-11-05 | -$963.00M 10-Q · filed 2015-11-05 | $122.00M derived: sum of 4 quarters · filed 2015-11-05 | ||||
| 2014-06-30 | -$18.00M 10-Q · filed 2015-08-04 | $60.00M 10-Q · filed 2015-08-04 | $1.15B derived: sum of 3 quarters · filed 2015-08-04 | $1.42B derived: sum of 4 quarters · filed 2015-08-04 | ||||
| 2014-03-31 | $78.00M 10-Q · filed 2015-05-06 | $1.16B derived: sum of 2 quarters · filed 2015-05-06 | $1.43B derived: sum of 3 quarters · filed 2015-05-06 | $1.10B derived: sum of 4 quarters · filed 2015-05-06 | ||||
| 2013-12-31 | $1.08B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | $1.35B derived: sum of 2 quarters · filed 2015-02-27 | $1.02B derived: sum of 3 quarters · filed 2015-02-27 | $572.00M 10-K · filed 2015-02-27 | ||||
| 2013-09-30 | $270.00M 10-Q · filed 2014-11-06 | $269.92M 10-Q · filed 2013-11-07 | -$63.00M derived: sum of 2 quarters · filed 2014-11-06 | -$513.00M 10-Q · filed 2014-11-06 | -$514.12M 10-Q · filed 2013-11-07 | -$1.37B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-06-30 | -$333.00M 10-Q · filed 2014-08-05 | -$331.75M 10-Q · filed 2013-08-06 | -$783.00M 10-Q · filed 2014-08-05 | -$784.04M 10-Q · filed 2013-08-06 | -$1.64B derived: sum of 3 quarters · filed 2015-02-27 | -$1.14B derived: sum of 4 quarters · filed 2015-02-27 | ||
| 2013-03-31 | -$452.00M 10-Q · filed 2014-05-07 | -$452.28M 10-Q · filed 2013-05-08 | -$1.31B derived: sum of 2 quarters · filed 2015-02-27 | -$802.98M derived: sum of 3 quarters · filed 2015-02-27 | -$1.89B derived: sum of 4 quarters · filed 2015-02-27 | |||
| 2012-12-31 | -$857.77M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-27 | -$350.98M derived: sum of 2 quarters · filed 2015-02-27 | -$1.43B derived: sum of 3 quarters · filed 2015-02-27 | -$997.00M 10-K · filed 2015-02-27 | -$996.49M 10-K · filed 2013-02-15 | |||
| 2012-09-30 | $506.79M 10-Q · filed 2013-11-07 | -$575.95M derived: sum of 2 quarters · filed 2013-11-07 | -$139.23M 10-Q · filed 2013-11-07 | |||||
| 2012-06-30 | -$1.08B 10-Q · filed 2013-08-06 | -$646.02M 10-Q · filed 2013-08-06 | ||||||
| 2012-03-31 | $436.72M 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | -$917.00M 10-K · filed 2014-02-21 | -$1.23B 10-K · filed 2013-02-15 | ||||||
| 2010-12-31 | -$2.22B 10-K · filed 2013-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |